Identification of dual inhibitors for EGFR(T790M/C797S) and VEGFR-2 in Non-Small Cell Lung Cancer from Moringa oleifera derived phytochemicals: An In-silico Approach

Author:

Munna Md. Masudur Rahman1,Tusar Md. Touki Tahamid1,Shanta Saima Sajnin1,Ahmed Md. Hossain1,Ali Md. Sarafat1

Affiliation:

1. Bangabandhu Sheikh Mujibur Rahman Science and Technology University

Abstract

Abstract

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality on a global scale for both men and women. At present, the treatment of NSCLC involves the use of tyrosine kinase inhibitors (TKIs), which specifically target EGFR. However, resistance mechanisms like the emergence of T790M and C797S EGFR mutations and increased expression of VEGFR-2 often impede the efficacy of various generations of TKIs. Thus, EGFR and VEGFR-2 offer a great opportunity to treat NSCLC through the development of multi-targeted drugs. Our study aims to identify potential inhibitors by thoroughly evaluating the biological activity of M. oleifera-derived compounds that could serve as novel dual inhibitors of EGFR(T790M/C797S) and VEGFR-2, resulting in a synergistic inhibitory effect on these signaling pathways. We identified five potential phytocompounds from M. oleifera (hesperetin, gossypetin, quercetagetin, gallocatechin, and epigallocatechin) that showed significant binding affinity in virtual screening and multi-stage molecular docking analysis with remarkable drug-likeness and ADMET properties. These selected drug candidates also strongly bound and stayed stable with the receptors during the 200 ns MD simulation and MM-GBSA calculation. These findings indicate that these therapeutic candidates have the capacity to precisely target both EGFR and VEGFR-2 and can potentially act on both of these pathways as a single agent.

Publisher

Research Square Platform LLC

Reference89 articles.

1. The epidemiology of lung cancer;Groot PM;Transl Lung Cancer Res,2018

2. Key molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review;Perlikos F;Crit Rev Oncol Hematol,2013

3. Novel drug discovery against breast and lung cancer using pharmacophore based 2H-1-benzopyran-2-one derivative;Mishra N;Res square,2022

4. Cancer incidence and mortality in China;Zheng R;J Natl Cancer Cent,2016

5. Chhikara BS, Parang K, Global Cancer Statistics (2022) The trends projection analysis. Chem Biol Lett. 2023;10(1):1–16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3